Trial Profile
Phase 2 trial of eribulin/S-1 combination therapy for advanced/recurrent breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Mar 2020
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms ERIS-Study
- 02 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 11 Sep 2014 New trial record